ClinicalTrials.gg
CompletedNCT02242370MicCATUpdated Sep 17, 2014

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

A Phase 4 interventional study of Low dose of telmisartan and High dose of telmisartan in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years to 93 Years. Per ClinicalTrials.gov, last updated 2014-09-17.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,045
Allocation
Non-randomized
Ages
20 Years to 93 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
2nd of 74
3,045 · median 381
Started
1999
with 8 others
Phase 4
26 of 122
none open now
Registered
99th of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 2nd largest by enrollment of the 74 interventional ones that give a count, is one of 9 that started in 1999, is one of 26 in phase 4, and was the 99th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 93 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 93 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg)
  • Signed form

Exclusion criteria

Exclusion Criteria:

  • Females of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,045 participants (actual)

Study arms

  • Experimental
    Telmisartan low dose

    Drug: Low dose of telmisartan

  • Experimental
    Telmisartan high dose

    Drug: High dose of telmisartan

Interventions

  • DrugLow dose of telmisartan
  • DrugHigh dose of telmisartan
06

What researchers measure

Primary outcomes

  1. Change in diastolic blood pressure

    Time frame: Pre-dose, up to 6 weeks after start of treatment

  2. Change in systolic blood pressure

    Time frame: Pre-dose, up to 6 weeks after start of treatment

  3. Changes from baseline in the quality of life (QOL) scores by patient self-assessment

    Time frame: Pre-dose, 6 weeks after start of treatment

Secondary outcomes

  1. Assessment of blood pressure control rate

    Time frame: Up to 6 weeks after start of treatment

  2. Assessment of systolic blood pressure response rate

    Time frame: Up to 6 weeks after start of treatment

  3. Assessment of diastolic blood pressure response rate

    Time frame: Up to 6 weeks after start of treatment

  4. Change from baseline in pulse pressure

    Time frame: Pre-dose, up to 6 weeks after start of treatment

  5. Number of patients with adverse events

    Time frame: Up to 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1999 and a primary completion of Nov 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Sep 17, 2014
Start
Sep 1999
Primary completionActual
Nov 2000
Last update
Sep 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02242370
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Sep 1999
Primary completion
Nov 2000
Last update
Sep 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion